Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BAZ2B | Q9UIF8 | 13/20 | 0.71 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.58 |
| ▸ | ATM | Q13315 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 3/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.58 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | CASP1 | P29466 | 1/20 | 0.58 |
| ▸ | CASP7 | P55210 | 1/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.58 |
| ▸ | CNR1 | P21554 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31117594 | 0.92 | BAZ2B (0.60) | BAZ2BLMNAPABPC1ATMSMN1; SMN2 | |
| SCHEMBL3722389 | 0.91 | BAZ2B (0.58) | BAZ2BLMNAPABPC1ATMSMN1; SMN2 | |
| SCHEMBL31117354 | 0.89 | BAZ2B (0.57) | BAZ2BLMNAPABPC1ATMSMN1; SMN2 | |
| SCHEMBL30228387 | 0.88 | TRPV1 (0.59) | BAZ2BLMNAPABPC1ATMSMN1; SMN2 | |
| SCHEMBL2832897 | 0.88 | LMNA (0.76) | BAZ2BLMNAPABPC1ATMSMN1; SMN2 | |
| SCHEMBL16140457 | 0.87 | BAZ2B (0.71) | BAZ2BLMNAPABPC1ATMSMN1; SMN2 | |
| SCHEMBL409534 | 0.87 | BAZ2B (0.71) | BAZ2BLMNAPABPC1ATMSMN1; SMN2 | |
| SCHEMBL5104575 | 0.87 | BAZ2B (0.71) | BAZ2BLMNAPABPC1ATMSMN1; SMN2 | |
| SCHEMBL3312381 | 0.86 | LMNA (0.57) | BAZ2BLMNAPABPC1ATMSMN1; SMN2 | |
| SCHEMBL21162488 | 0.86 | BAZ2B (0.74) | BAZ2BLMNAPABPC1ATMSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113121527-B | Tricyclic compounds and uses thereof | 上海辉启生物医药科技有限公司 | 2024-09-06 | — | — | CN | disclosed |
| EP-3735411-B1 | 1,3,4,5-TETRAHYDRO-2H-PYRIDO[4,3-B]INDOLE DERIVATIVES FOR THE TREATMENT, ALLEVIATION OR PREVENTION OF DISORDERS ASSOCIATED WITH TAU AGGREGATES LIKE ALZHEIMER`S DISEASE | AC IMMUNE SA (CH) | 2024-07-10 | — | — | EP | disclosed |
| EP-3735411-B1 | 1,3,4,5-TETRAHYDRO-2H-PYRIDO[4,3-B]INDOLE DERIVATIVES FOR THE TREATMENT, ALLEVIATION OR PREVENTION OF DISORDERS ASSOCIATED WITH TAU AGGREGATES LIKE ALZHEIMER`S DISEASE | AC IMMUNE SA (CH) | 2024-07-10 | — | — | EP | disclosed |
| US-20240197694-A1 | MODIFIED PROTEINS AND PROTEIN BINDERS | CULLGEN (SHANGHAI), INC. (CN) | 2024-06-20 | — | — | US | disclosed |
| CN-117642397-A | Modified proteins and protein binders | 上海睿跃生物科技有限公司 | 2024-03-01 | — | — | CN | disclosed |
| US-11814378-B2 | Compounds for the treatment, alleviation or prevention of disorders associated with Tau aggregates | AC IMMUNE SA (CH) | 2023-11-14 | — | — | US | disclosed |
| US-11814378-B2 | Compounds for the treatment, alleviation or prevention of disorders associated with Tau aggregates | AC IMMUNE SA (CH) | 2023-11-14 | — | — | US | disclosed |
| US-11814378-B2 | Compounds for the treatment, alleviation or prevention of disorders associated with Tau aggregates | AC IMMUNE SA (CH) | 2023-11-14 | — | — | US | disclosed |
| CN-111757882-B | Compounds for treating, alleviating or preventing conditions associated with tau aggregates | AC免疫有限公司 | 2023-08-22 | — | — | CN | disclosed |
| WO-2022194087-A1 | MODIFIED PROTEINS AND PROTEIN BINDERS | CULLGEN (SHANGHAI) , INC. (CN) | 2022-09-22 | — | — | WO | disclosed |
| EP-3735411-A1 | 1, 3, 4, 5-TETRAHYDRO-2H-PYRIDO[4,3-B]INDOLE DERIVATIVES FOR THE TREATMENT, ALLEVIATION OR PREVENTION OF DISORDERS ASSOCIATED WITH TAU AGGREGATES LIKE ALZHEIMER'S DISEASE | AC Immune SA (CH) | 2020-11-11 | — | — | EP | disclosed |
| US-20200148679-A1 | Novel compounds for the treatment, alleviation or prevention of disorders associated with Tau aggregates | AC IMMUNE SA (CH) | 2020-05-14 | — | — | US | disclosed |
| US-20200148679-A1 | Novel compounds for the treatment, alleviation or prevention of disorders associated with Tau aggregates | AC IMMUNE SA (CH) | 2020-05-14 | — | — | US | disclosed |
| US-10633383-B2 | Compounds for the treatment, alleviation or prevention of disorders associated with Tau aggregates | AC IMMUNE SA (CH) | 2020-04-28 | — | — | US | disclosed |
| US-10633383-B2 | Compounds for the treatment, alleviation or prevention of disorders associated with Tau aggregates | AC IMMUNE SA (CH) | 2020-04-28 | — | — | US | disclosed |
| WO-2019158731-A1 | PHARMACEUTICAL 6,5 HETEROBICYCLIC RING DERIVATIVES | UCB BIOPHARMA SPRL (BE) | 2019-08-22 | — | — | WO | disclosed |
| WO-2019134978-A1 | 1, 3, 4, 5-TETRAHYDRO-2H-PYRIDO[4,3-B]INDOLE DERIVATIVES FOR THE TREATMENT, ALLEVIATION OR PREVENTION OF DISORDERS ASSOCIATED WITH TAU AGGREGATES LIKE ALZHEIMER'S DISEASE | AC IMMUNE SA (CH) | 2019-07-11 | — | — | WO | disclosed |
| WO-2019134978-A1 | 1, 3, 4, 5-TETRAHYDRO-2H-PYRIDO[4,3-B]INDOLE DERIVATIVES FOR THE TREATMENT, ALLEVIATION OR PREVENTION OF DISORDERS ASSOCIATED WITH TAU AGGREGATES LIKE ALZHEIMER'S DISEASE | AC IMMUNE SA (CH) | 2019-07-11 | — | — | WO | disclosed |
| US-20190211012-A1 | Novel compounds for the treatment, alleviation or prevention of disorders associated with Tau aggregates | AC IMMUNE SA (CH) | 2019-07-11 | — | — | US | disclosed |
| US-20190211012-A1 | Novel compounds for the treatment, alleviation or prevention of disorders associated with Tau aggregates | AC IMMUNE SA (CH) | 2019-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190211012-A1 | Novel compounds for the treatment, alleviation or prevention of disorders associated with Tau aggregates | MAPT, MAP1LC3A, MAP1LC3B | BAZ2B 1307/4885LMNA 2338/4885PABPC1 1632/4885 |
| US-10633383-B2 | Compounds for the treatment, alleviation or prevention of disorders associated with Tau aggregates | MAPT, MAP1LC3A, TUBB3 | BAZ2B 1631/4885LMNA 2017/4885PABPC1 1767/4885 |
| US-20240197694-A1 | MODIFIED PROTEINS AND PROTEIN BINDERS | DCAF1, DDB1, CUL4A | BAZ2B 98/4885LMNA 2501/4885PABPC1 129/4885 |
| US-20200148679-A1 | Novel compounds for the treatment, alleviation or prevention of disorders associated with Tau aggregates | MAPT, MAP1LC3A, MAP1LC3B | BAZ2B 1307/4885LMNA 2338/4885PABPC1 1632/4885 |
| US-11814378-B2 | Compounds for the treatment, alleviation or prevention of disorders associated with Tau aggregates | MAPT, MAP1LC3A, TUBB3 | BAZ2B 1631/4885LMNA 2017/4885PABPC1 1767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.